Murray Stewart
Directeur/Membre du Conseil chez X4 PHARMACEUTICALS, INC.
Fortune : 193 419 $ au 31/05/2024
Relations actives
| Nom | Sexe | Age | Sociétés liées | Collaboration |
|---|---|---|---|---|
| Paula Ragan | M | 54 | 10 ans | |
| Paul Carter | M | 63 |
VectivBio AG
 VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 14 ans |
| Mark Dipaolo | M | 53 | 3 ans | |
| Sandipkumar S. Kapadia | M | 54 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 ans |
| Stephen P. Squinto | M | 67 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 ans |
| Chahra Khaoua Epouse Louafi | F | 53 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 4 ans |
| Odysseas Kostas | M | 49 | 1 ans | |
| Johannes G. C. P. Schikan | M | 66 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 ans |
| Phil Thomson | M | - | 13 ans | |
| Luca Santarelli | M | 55 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 ans |
| Emma Walmsley | F | 55 | 14 ans | |
| Thomas Woiwode | M | 52 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | 5 ans |
| Adam Mostafa | M | 44 | 6 ans | |
| Mary DiBiase | M | 63 | 7 ans | |
| David Connolly | M | - | 5 ans | |
| Jesse Goodman | M | 72 | 8 ans | |
| Keith Horn | M | 66 | 1 ans | |
| Patrice Bonfiglio | F | 40 | 1 ans | |
| Tony Wood | M | - | 7 ans | |
| Diane Sullivan | F | 62 | 1 ans | |
| Françoise de Craecker | F | 62 | 3 ans | |
| Michael Wyzga | M | 69 | 6 ans | |
| Stuart Arbuckle | M | 58 | 5 ans | |
| Paul Cohen | M | 49 | 1 ans | |
| Jennifer Good | F | 59 | 5 ans | |
| David McGirr | M | 69 | 7 ans | |
| Camille Bedrosian | M | 71 | 4 ans | |
| Lynn Tetrault | F | 61 | 4 ans | |
| Louis Sterling | M | 45 | 1 ans | |
| Bill Aliski | M | 75 | 5 ans | |
| Alison Lawton | F | 62 | 4 ans | |
| Gary Bridger | M | 61 | 6 ans | |
| Timothy Woodthorpe | M | - | 24 ans | |
| Pamela Cramer | F | 50 | 3 ans | |
| Jim Flaherty | M | - | 5 ans | |
| Frannie DeFranco | F | - | 14 ans | |
| Anita Kidgell | F | - | 16 ans | |
| Sally Jackson | F | - | 23 ans | |
| Elisabeth Crönert-Bendell | M | - | 3 ans | |
| Joseph Shulman | M | 49 | 4 ans | |
| Mark Baldry | M | 60 | 2 ans | |
| Diana Conrad | F | - | 8 ans | |
| Yann Mazabraud | M | 51 | 4 ans | |
| R. Woods | M | 56 | 1 ans | |
| Christophe Arbet-Engels | M | - | 1 ans | |
| María Cristina de Luna Basagoiti | F | - | 14 ans | |
| Luke Miels | M | - | 7 ans | |
| Art Taveras | M | 60 | 4 ans | |
| Victoria Whyte | F | - | 15 ans | |
| Christian Meyer | M | 56 |
VectivBio AG
VectivBio AG BiotechnologyHealth Technology VectivBio AG is a clinical-stage biotechnology company. The firm focuses on developing transformational therapeutics for patients living with serious and rare diseases. Its program apraglutide, is a next-generation GLP-2 analog for the treatment of short bowel syndrome (SBS). The company was founded by Luca Santarelli in 2019 and is headquartered in Basel, Switzerland. | - |
| Jennifer Chien | F | 49 | 4 ans | |
| Barbara Beirer | M | - |
Vivli Center For Global Clinical Research Data
| - |
Graphique Relationnel
Relation dans plusieurs entreprises
Anciennes relations
Statistiques
| Pays | Relations | % du total |
|---|---|---|
| Royaume-Uni | 46 | 46,00% |
| Etats-Unis | 29 | 29,00% |
| Irlande | 12 | 12,00% |
| Suisse | 11 | 11,00% |
| Canada | 4 | 4,00% |
Age des relations
Actives
Passées
Homme
Femme
Administrateurs
Exécutifs
Provenance des relations
- Bourse
- Insiders
- Murray Stewart
- Réseau Personnel
